As laboratories face the challenge of screening many samples for SARS-CoV-2, lab managers have turned to the use of automation to address key concerns.
List view / Grid view
Filter the results
1 March 2021 | By Bruker Scientific, LLC
Sign up for our free webinar that will focus on the detailed description of the workflow and case studies of BAMS™ assays developed for targets relevant to neurology and virology.
26 February 2021 | By Domain Therapeutics
Register for our webinar which will focus on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
eBook: Revolutionise your lab with a cutting-edge bioprocess platform to drive quality and efficiency
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Researchers have found that the S1/S2 cleavage of the SARS-CoV-2 Spike protein could be a potential target for COVID-19 therapeutics.
Using liquid chromatography/mass spectrometry, researchers have revealed no major differences in glycan structures in two prion strains.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.
Application note: Evaluation of different ion-pairing reagents for LC/UV and LC/MS analysis of oligonucleotides
The effect of various ion pairing reagents (amines and acidic counterions) on the LC/UV and LC/MS analysis of oligonucleotides (ONs) has been studied.
A better understanding of the role of four-stranded DNA (G-quadruplex) could enhance cancer therapeutics, said the developers of the probes.